Novo Nordisk A/S (FRA:NOV)

Market Cap	291.94B
Revenue (ttm)	40.64B
Net Income (ttm)	14.02B
Shares Out	n/a
EPS (ttm)	3.15
PE Ratio	20.82
Forward PE	18.40
Dividend	1.53 (2.34%)
Ex-Dividend Date	Mar 28, 2025

Volume	60
Average Volume	315
Open	63.50
Previous Close	64.26
Day's Range	63.50 - 65.53
52-Week Range	50.95 - 139.58
Beta	n/a
RSI	63.18
Earnings Date	Aug 6, 2025

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 77,349
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NOV

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK